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ABSTRACT
The histiocytoses are rare tumors characterized by the primary accumulation 
and tissue infiltration of histiocytes and dendritic cells. Identification of the activating 
BRAFV600E mutation in Erdheim-Chester disease (ECD) and Langerhans cell 
histiocytosis (LCH) cases provided the basis for the treatment with BRAF and/or 
MEK inhibitors, but additional treatment options are needed. Twenty-four cases of 
neoplastic histiocytic diseases [11 extrapulmonary LCH, 4 ECD, 4 extranodal Rosai-
Dorfman disease (RDD), 3 follicular dendritic cell sarcoma (FDCS), 1 histiocytic 
sarcoma (HS) and 1 blastic plasmacytoid dendritic cell neoplasm (BPDCN)] were 
analyzed using immunohistochemical and mutational analysis in search of biomarkers 
for targeted therapy. BRAF V600E mutations were detected in 4/11 LCH and 4/4 ECD 
cases. A pathogenic PTEN gene mutation and loss of PTEN protein expression were 
identified in the case of HS. Increased expression of PD-L1 (≥2+/≥5%) was seen in 
3/4 ECD, 7/8 LCH, 3/3 FDCS and 1/1 HS, with overall 81% concordance between 2 
antibodies used in the study (SP142 vs. MAB1561 clone). These results show for the 
first time significant expression of the PD-L1 immune checkpoint protein in these 
disorders, which may provide rationale for addition of immune check-point inhibitors 
in treatment of disseminated and/or refractory histiocytoses.
INTRODUCTION
The proliferative histiocytoses encompass a broad 
spectrum of rare tumors with clinical behavior ranging 
from spontaneous regression to highly aggressive disease 
with fatal outcome [1]. They are characterized by the 
accumulation and tissue infiltration of immunologically 
active cells, including T cells, eosinophils, macrophages 
and dendritic cells. The histologic types include 
Langerhans cell histiocytosis (LCH), Rosai-Dorfman 
disease (RDD), Erdheim-Chester disease (ECD), follicular 
dendritic cell sarcoma (FDCS) and histiocytic sarcoma. 
In addition, blastic plasmacytoid dendritic cell neoplasm 
(BPDCN) shares some characteristics with plasmacytoid 
monocytes (dendritic cells). Identification of the activating 
BRAF V600E mutation in a subset of histiocytoses (ECD 
and LCH, 50-100%) has opened a new avenue for the 
treatment of these disorders with BRAF and MEK 
inhibitors [1-5]. Studies of Bubolz et al. [3] and Haroche 
et al. [6-7] demonstrated some efficiency of the BRAF 
inhibitor vemurafenib in the treatment several patients 
with multisystemic and refractory ECD and LCH. 
The Programmed Cell Death 1 (PD-1 or CD279) 
protein is a T-cell co-inhibitory receptor, which upon 
binding of its ligand PD-L1 (CD274) expressed by tumor 
cells, inhibits cytokine production and cytotoxic activity of 
PD-1+ tumor infiltrating T-lymphocytes, facilitating tumor 
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progression (escape phase of cancer immunoediting). The 
suppression of PD-L1/PD-1 interaction using specific 
inhibitors has shown promising effects in the treatment 
of several advanced cancers, most notably in melanoma, 
renal cell carcinoma and non-small cell lung cancer [8-10].
Because normal dendritic cells and macrophages 
express PD-L1 [11], we investigated its expression 
by neoplasms of dendritic and related histiocytic cell 
neoplasms. 
RESULTS
BRAF V600E and other genes’ mutations
The BRAF V600E mutation was identified in 8 out of 
24 cases (33%) including 4/4 ECD (100%) and 4/11 LCH 
(36%) while other histiocytoses harbored no BRAF V600E 
mutations (Table 1). One patient with BRAFV600E-
mutated LCH involving the parietal bone harbored 
additional variants of unknown significance including 
BRAF W604C, EGFR (A743V) and cMET (V378I), while 
another patient with BRAFV600E-mutated LCH had a 
JAK3 (V722I) mutation. The BRAF V600E mutant protein 
was detected in 3 out of 5 BRAF V600E mutated cases 
(60%) using immunohistochemistry (Figures 2D, 3C, 
4B, and 4D) while the single BRAFV600E-sequencing-
negative RDD case stained positively for BRAFV600E 
protein (Figure 1D). A case of HS that was devoid of 
a BRAF V600E mutation harbored pathogenic, PTEN 
mutation (c.635-7_639del; a splice site mutation that 
abolishes the conserved splice region at exon 7 of PTEN 
gene) confirmed by the loss of PTEN protein by IHC 
(Figure 2C). A variant of unknown significance involving 
SMAD4 (T521I mutation) was detected in a patient with 
BRAF-negative extranodal RDD. 
PD-1 and PD-L1 expression
Overexpression of PD-L1 (≥2+/≥5%) was seen in 
the majority of cases (3/4 ECD, 7/8 LCH, 3/3 FDCS and 
1/1 HS, Table 1, Figures 1C, 2B, 3B, 4A, and 4C), but 
Figure 1: A case of Rosai-Dorfman disease: A. Hematoxylin and Eosin [H&E] stained slide; B. S100 stain highlights rare disease-
specific large histiocytes with emperipolesis (negative lymphocytes within S100 positive cytoplasm); C. Lack of PD-L1 staining in large 
histiocytes (scattered positive reactive cells) and D. BRAFV600E scattered positive large histiocytes. 
Oncotarget19821www.impactjournals.com/oncotarget
Table 1: Overview of BRAF, other mutations and PD-L1 status in various neoplastic histiocytoses
Histotype 
(n=24)
BRAFV600E
(%#)
PD-L1 
expression* Other mutations
Langerhans cell histiocytosis 
(n=11) 36% 88%
cMET, EGFR, BRAF 
W604C (1 case)** 
JAK3 (1 case)**
Rosai-Dorfman disease
(n=4) 0%
## 0% SMAD4 (1 case)***
Erdheim-Chester disease 
(n=4) 100% 100% None
Follicular dendritic cell sarcoma 
(n=3) 0% 100% None 
Histiocytic sarcoma 
(n=1) 0% 100% PTEN
Blastic plasmacytoid dendritic cell 
neoplasm (n=1) 0% 0% None 
* 81% concordance was obtained between MAB1561 and SP142 antibodies. 
** Both LCH cases also harbored BRAF V600E mutation. All described mutations represent variants of 
unknown significance.
***Variant of unknown significance.
# Using COBAS method
## A single case of RDD which was negative for detection of mutations in BRAF (Both Cobas and NGS) 
was positive using IHC for mutated BRAF V600E protein.
Figure 2: A. H&E slide of a case of histiocytic sarcoma; B. The tumor cells were strongly positive for PD-L1; C. The tumor completely 
lost PTEN protein expression due to the PTEN gene mutation (normal PTEN expression is seen in endothelium); D. No BRAFV600E 
mutant protein expression was observed.
Oncotarget19822www.impactjournals.com/oncotarget
Figure 3: A. Langerhans cell histiocytosis (LCH), H&E slide; B. Large neoplastic Langerhans cells are strongly positive for PD-L1; C. 
BRAFV600E mutant protein expression (BRAF gene mutation confirmed) D. Tumor-infiltrating lymphocytes were positive for PD-1.
Figure 4: Co-localization of BRAFV600E protein and PD-L1 in histiocytic tumors. A. PD-L1 and B. BRAFV600 mutant 
protein expression in 2 consecutive sections (8 microns apart) showing similar topographic distribution of PD-L1 and BRAFV600E; C. 
and D. are double IHC for PD-L1 (red) and BRAFV600E (brown) showing co-localization of both stains to the same Langerhans cell (D 
– center).
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not in RDD and BPDCN. The expression of PD-L1 in 
neoplastic cells was appreciatively stronger (2+ and 3+ 
staining intensity) than in normal macrophages or dendritic 
cells present at the periphery of the lesions (1+). We 
found overall 81% concordance between two antibodies 
directed against PD-L1 (SP142 and MAB1561 clones). 
The highest concordance rate was seen in RDD (100%) 
and LCH (89%) while MAB1561 antibody appeared to be 
more sensitive in detection of positive cells in ECD (3+/3, 
100%) than SP142 antibody that was positive in only 1 out 
of 4 tested cases (25%). 
Figures 3 and 4 illustrate a case of LCH with 
BRAFV600E mutation expressing PD-L1 in neoplastic 
Langerhans cells, which in the consecutive sections show 
co-localization of BRAFV600E and PD-L1 positive cells. 
Double immunohistochemical stain also showed both PD-
L1 (red) and BRAFV600E (brown) proteins co-localizing 
to the same multinucleated Langerhans cell.
PD-1 expressing tumor infiltrating lymphocytes 
were variably present in all the disease subtypes (Figure 
3D). 
DISCUSSION
The histiocytoses are rare neoplasms with highly 
unpredictable clinical course ranging from spontaneous 
regression to highly aggressive disease with fatal outcome 
[1]. In the present study we explored the expression of 
the key checkpoint molecules, PD-1 and PD-L1, in these 
disorders along with the detection of gene mutations. The 
mutational analyses confirmed overall low number of 
mutated genes in histiocytoses [2, 15] with the pathogenic 
BRAF V600E mutations characterizing the majority of 
LCH and ECD [1-5]. These data support the rationale for 
the use of therapy targeting BRAF and/or MEK1 inhibitors 
for selected refractory and multisystem histiocytoses 
[3, 5-7]. Mutations have also been reported involving 
reported KRAS, NRAS and PIK3CA mutations in BRAF 
V600E -negative ECD [5, 16, 17]. We also found several 
additional mutations/variants of unknown significance 
(e.g. cMET, EGFR).
Although Go et al. [18] reported a high frequency of 
BRAF V600E mutations in histiocytic sarcomas, a single 
case in our series harbored no BRAF V600E; instead a 
pathogenic PTEN mutation followed by PTEN protein 
loss was detected. Carrasco et al. reported partial and 
complete PTEN gene deletions with concomitant loss of 
PTEN expression in 2 of 6 HS cases [19]. 
Our study for the first time demonstrates that PD-
L1 frequently shows high levels of expression in systemic 
histiocytoses. PD-1 represents an immunosuppressive 
molecule whose expression on T-lymphocytes and other 
immune cells is an important part of immune surveillance. 
Activation by the ligand (PD-L1) results in attenuation 
of the immune response [9]. The ligand (PD-L1) may 
be aberrantly expressed on the neoplastic cells or on the 
immune cells at the tumor/host interface, and therapy-
predictive contribution of either of the components still 
needs to be determined [8]. Inhibition of the PD-1/PD-L1 
axis has been shown to be a promising therapeutic target in 
various cancers, particularly in renal cell carcinoma, non-
small cell lung carcinoma and malignant melanoma [8-10]. 
We and others also reported on the expression of PD-L1 in 
a variety of both solid and hematological malignancies [8, 
12, 20-22], but not yet in neoplastic histiocytic diseases. 
A study conducted by Muenst et al. [23] reported PD-1 
expression in a single case of RDD. Our data indicate that 
a subset of histiocytoses, including LCH, ECD, FDCS, and 
HS, may be potentially amenable to the targeted therapy 
with immune checkpoint inhibitors based on the high 
levels of expression of these check-point molecules. This 
might be particularly relevant for the subset of systemic 
histiocytoses that are refractory to conventional and/or 
targeted therapies. The results also suggest the possibility 
of combining targeted small molecule targeted agents with 
PD-1/PD-L1 inhibitors. We used two different antibodies 
against PD-L1 to explore their diagnostic utility. Our 
results indicate a good concordance (81%) between the 
two antibodies with the MAB1561 antibody being a more 
sensitive than SP142 antibody. Future studies are needed 
to test the predictive value and utility of PD-L1 antibodies 
and immunohistochemistry as a method for directing 
targeted PD-1/PD-L1 therapy (i.e., companion diagnostic 
testing). 
Our results of the high level of expression of PD-L1 
expression in histiocytoses, along with the frequent BRAF 
and other ERK pathway gene mutations provide additional 
support for testing combination therapeutic approaches 
for patients with multisystem and/or refractory forms of 
histiocytoses. 
MATERIALS AND METHODS
Samples and patients
The study included 24 patients (14 males and 10 
females; age range, 2-74 years, mean: 42 years) diagnosed 
with histiocytic diseases including 4 cases of extranodal 
RDD, 11 LCH (10 extra pulmonary and 1 pulmonary), 4 
ECD (2 retroperitoneal soft tissue and 2 involving cranial 
bones), 3 follicular dendritic cell sarcomas (FDCS, 
involving thorax and colon, respectively), 1 HS (bone) and 
1 blastic plasmacytoid dendritic cell neoplasm (BPDCN, 
skin). All samples were reviewed by a board-certified 
pathologist (Z.G.) to confirm the diagnosis. All testing 
had been performed in Caris Life Sciences (Phoenix, 
Arizona) facility which is CLIA certified and CAP, ISO 
and NYSDOH accredited.
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Immunohistochemistry (IHC)
Formalin-fixed paraffin-embedded (FFPE) tissue 
sections were stained for PD-L1 [clones: anti-human PD-
L1 rabbit monoclonal antibody SP142, Spring Bioscience; 
and anti-human MAB1561 mouse monoclonal antibody, 
R&D Systems] and PD-1 (monoclonal antibody NAT105, 
Cell Marque). The tumor sample was considered positive 
for PD-L1 if 2+ intensity (complete membranous staining) 
was observed in ≥5% of cells [8]. Any extent of the 
presence of PD-1+ tumor infiltrating lymphocytes was 
considered positive [12]. BRAFV600E mutant protein was 
detected using VE1 antibody (mouse monoclonal antibody, 
Ventana Medical Systems, Tucson, AZ) [13, 14]. PTEN 
expression was analyzed using monoclonal 6H2.1 antibody 
(Dako, Carpinteria, CA). Selected cases were stained 
using double immunohistochemical staining (Figure 
4) with diaminobenzidine tetra hydrochloride (DAB) 
as a brown chromogen for horseradish peroxidase and 
Naphtol and Fast red chromogen for alkaline phosphatase. 
Additional immunohistochemical tests were performed to 
confirm the diagnosis and to highlight the pathogenic cell 
population (e.g. S-100, CD68, CD1a detection). 
Mutational analysis
Next-generation sequencing (NGS)
Direct sequencing analysis was performed on 
genomic DNA isolated from FFPE samples using 
the Illumina MiSeq platform. Specific regions of the 
genome were amplified using the Illumina TruSeq 
Amplicon Cancer Hotspot panel. The panel included 46 
genes sequenced by NGS and can be found at: http://
www.carismolecularintelligence.com/next-generation-
sequencing-profile. All variants reported by NGS are 
detected with >99% confidence based on the frequency 
of the mutation present and the amplicon coverage using 
a mutation frequency threshold of 10%. All regions that 
are sequenced achieve a minimum of 100x coverage and 
overall samples have an average coverage of >500x. 
Cobas BRAF V600E analysis
BRAF mutation analysis was done using the Cobas® 
4800 BRAF V600 Mutation Test (Roche Diagnostics). 
DNA was isolated from the FFPE tumor samples using 
standard laboratory procedures. Real-time PCR was used 
to amplify the exon 15 of the BRAF gene. Following 
amplification, a set of differentially labeled fluorescent 
probes were utilized to detect normal and mutant V600 
sequences. 
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